Leslie Andersen

Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA

D. Bernstein, L. Jacques, R. Forth, 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone

A. Woodcock, W. Busse, E. Bleecker, 2013, Thorax.

Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?

P. Dorinsky, S. Yancey, J. Stauffer, 2008, Respiratory medicine.

Authors’ reply to ‘Safety and tolerability of fluticasone furoate/vilanterol’

W. Busse, Leslie Andersen, 2013, Thorax.

Effect of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) on risk of severe exacerbations in asthma

A. Woodcock, W. Busse, E. Bleecker, 2012 .

Comparison of Once Daily Fluticasone Furoate/Vilanterol With Twice Daily Fluticasone Propionate/Salmeterol in Patients With Controlled Asthma

D. Bernstein, L. Jacques, R. Forth, 2017 .

Functional Chest Pain: Esophageal or Overlapping Functional Disorder

J. Remes-Troche, Satish S. C. Rao, R. Mudipalli, 2007, Journal of clinical gastroenterology.

Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.

H. Ortega, C. Scott-Wilson, L. Schoaf, 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial

A. Woodcock, W. Busse, E. Bleecker, 2013, Thorax.

An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies

W. Busse, L. Frith, L. Jacques, 2016, Pulmonary Therapy.